<code id='8C9C634E0A'></code><style id='8C9C634E0A'></style>
    • <acronym id='8C9C634E0A'></acronym>
      <center id='8C9C634E0A'><center id='8C9C634E0A'><tfoot id='8C9C634E0A'></tfoot></center><abbr id='8C9C634E0A'><dir id='8C9C634E0A'><tfoot id='8C9C634E0A'></tfoot><noframes id='8C9C634E0A'>

    • <optgroup id='8C9C634E0A'><strike id='8C9C634E0A'><sup id='8C9C634E0A'></sup></strike><code id='8C9C634E0A'></code></optgroup>
        1. <b id='8C9C634E0A'><label id='8C9C634E0A'><select id='8C9C634E0A'><dt id='8C9C634E0A'><span id='8C9C634E0A'></span></dt></select></label></b><u id='8C9C634E0A'></u>
          <i id='8C9C634E0A'><strike id='8C9C634E0A'><tt id='8C9C634E0A'><pre id='8C9C634E0A'></pre></tt></strike></i>

          Home / hotspot / explore

          explore


          explore

          author:leisure time    Page View:8541
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In